NovioSense Announces Successful Clinical Trial and Secures 4th Round Financing for Its Tear Glucose Sensor with Noviotech as coinvestor

October 24th, 2016

New US Investors and Harry G. Mitchell Join the NovioSense Team

NIJMEGEN, Netherlands–October 24, 2016

Following successful clinical trials in 2015, NovioSense BV, today announced they had closed their 4th financing round for the next clinical validation phase of their smartphone based tear glucose sensor device, to provide an accurate, pain-free and conveniently placed glucose sensor to address the growing diabetes epidemic impacting people’s lives and overwhelming healthcare systems worldwide.

NovioSense has developed a flexible miniature sensor that rests in the lower eyelid and provides glucose measurements directly to a smartphone. NovioSense provides the first of its kind eye-wearable, wireless, battery-free glucose sensor. “Our product will deliver pain-free continuous glucose monitoring to all individuals with diabetes at an affordable price. By utilising NFC technology found in most smartphones, our pain-free non-invasive sensor platform is employed by users to continuously monitor glucose readings, an effective component to any glucose management system,” said NovioSense CEO Dr Christopher Wilson.

The financing round including two new US based investors will build more clinical accuracy data of the sensor platform compared to competing minimally invasive devices. NovioSense will report its second phase clinical data in the first half 2017 and will pursue market clearance in 2019.

As part of the new investment, NovioSense announced that Harry G. Mitchell, a senior executive with more than twenty-five years’ experience in medical device, diabetes and related complication spaces joined the company as Executive Vice President of Business Development.

“Through his finance and C-Level experience, Harry Mitchell is a leading business developer in the medical device and diabetes space, and recently Executive Director and Co-Founder of The Joslin Institute for Technology Translation at the Joslin Diabetes Center in Boston Massachusetts. Throughout his career, Harry has consistently demonstrated exceptional business acumen building companies, with M&A and publically traded initiatives. We are extremely privileged and excited to have Harry on board as we continue to grow and explore several product opportunities using our analyte sensing portfolio.” said Dr Wilson CEO NovioSense BV.

“I am looking forward to continuing my work with the NovioSense Team and pursuing opportunities to introduce technologies developed by the Company that will make a commercial impact in Diabetes and related fields in the US and other key markets.” said Harry Mitchell EVP of Business Development at NovioSense BV.

NovioSense BV
Website: www.noviosense.com
Contact: c.wilson@noviosense.com

back to news overview

René Aerts

Partner

Originally, I have an Organic Chemistry/ PharmacoChemistry background. Later I moved into broader LifeSciences and Biologicals areas. I have long career in the LifeScience and Animal Health industry, such as my former membership of the executive committee at Merck AH. Merck AH is the animal health division of Merck Inc. with about 3.5 B€ annual sales and a global presence in companion animals as well as food animals.

I have had Executive roles in a global top 3 Animal Health company (MSD AH and it’s predecessors). My areas of expertise lie in Antibiotics, Regulatory Affairs, Manufacturing, Vaccine R&D and M&A projects.

At NovioCap, I am interested in supporting individuals and teams to help transfer innovative ideas into products on the market. With my experience in executive roles, I support in business plan formation and execution.

follow me on LinkedIn

Hans Hanssen

Partner

My background lies in solid state physics and inorganic chemistry. Early in my career I became an entrepreneur. I started companies in differents fields such as integrated circuits, medical devices and biomaterials.

I have executive experience in medical device manufactoring and a lot of experience in bringing ideas to the market by scouting opportunities. I like to work with highly motivated people. In my work, I am especially interested in new, innovative ideas that will positively influence the world.

Within NovioCap I scout new technologies to develop further and like to share my experience.

follow me on LinkedIn

Rob Tweehuysen

Partner

My background lies in engineering and as an entrepreneur in medical technology and new materials. I have experience in the application and marketing of early phase developments or startup wherein financing plays an important role.

I have founded several companies, some of which have come to an exit. My areas of expertise are in mechatronics, IP development, manufacturing, financing and M&A.

NovioCap is the ideal incubator to take promising startups to the next phase, because of its experienced and diverse team. It is essential to form strong teams to convert innovative ideas into products on the market.

follow me on LinkedIn

Jos Verstegen

Partner

As Director/CFO of Synbra, I was responsible for the strategy, personnel, IT, finance and governance matters. Synbra is a pure-play developer and manufacturer of particle foam products made of expanded polystyrene and has a track record as innovation leader in the industry with above market performance.

I have over 41 years of industry experience and transformed businesses through continuous product innovation, operational excellence and M&A. My experience lies in the insulation and packaging solutions markets.

At NovioCap, I deliver a contribution in the challenging trajectory it is going through and enjoy being member of a team with different backgrounds and experience. As a CFO, I have a broad perspective on business development

follow me on LinkedIn

Herman Walda

Partner

I retired as vice president of the regional Court of Gelderland. Nevertheless, I am still working as a counselor specialized in civil law. In the field of dispute resolution, I have experience as chairman of the Disciplinary Courts of public/private partnership organisations, as well as chairman of various Arbitration Committees. At NovioCap, I operate as an advisor in strategic and legal matters.

Cartesian Optics

Cartesian Optics (CO) develops lenses with superior image quality. Inspired by the work of Descartes in the 17th-century, CO implements a innovative way of calculating lenses. The form of the CO lenses can be found in one of the wonders of nature: the eye.

The first application of the new lens calculation are in the multifocal glasses market. Typically, a multifocal lens is design leads to some distortion of your side vision. This can cause blurry vision and even leads to falling when walking down the stairs. CO multifocal glasses do not excibit this disadvantage and gives a perectly clear view through the whole glass.

NovioPonics

We believe that the sustainability of crop protection needs to be redefined beyond traditional measures and genetic engineering. We are taking up the challenge to redefine the sustainability of crop protection by creating a smart material which lowers the pesticide waste and reduces their negative impact.

open website

NovioTech

NovioTech is open for new starters or ideas with a focus on innovative technological and medical applications.

NovioScan

NovioScan is founded in 2014 and holds its office at the NovioTech Campus in Nijmegen, The Netherlands. The development of wearable ultrasound SENS-U innovation was a result of technical innovation combined with the clinical need to help children who do not sense their bladder. The SENS-U innovation is a wearable ultrasound sensor that measures the level in the bladder. After 4 years of development Novioscan launched the SENS-U KIDS in 2018 and made it available for the treatment of children in the age of 6-12 years.

NovioScan is acquired by Essity in April 2020. Essity is the leading global player in incontinence products with the TENA brand. The SENS-U technology is an innovative solution that will strengthen Essity’s offering in incontinence care and give consumers an opportunity to live a healthier and more active life

open website

Divested in: April 2020

NovioSense

NovioSense is a revolution in non-invasive glucose monitoring utilising wireless data and power to continually monitor glucose levels in tear fluid. It combines robust enzymatic detection technology with innovative immobilisation and wireless sensor technologies to provide a flexible sensor

NovioSense’s flexible, spring-shaped coil drops in behind the lower eyelid—something users can do themselves—and naturally stays put. The spring-shaped electrodes are coated in a biopolymer containing an immobilized enzyme that, when exposed to glucose, starts a chemical reaction. That reaction results in the oxidation of hydrogen peroxide, which can be detected by the electrodes using a chronoamperometric measurement.

Divested in: 2020

Chiralix

Chiralix is dedicated to supporting Life Sciences researchers across the globe, by supplying a unique range of building blocks, reference standards, metabolites, impurities, stable isotope-labeled compounds (2H, 13C and 15N) and more. With most of our product offerings available from stock and with our passion for quality, we are your dependable source for specialty research chemicals.

In 2018, Symeres (former: MercachemSyncom) acquired Chiralex. Symeres is a leading European small molecule contract research and manufacturing organization.

open website

Divested in: July 2018

Encapson

Encapson is a medical technology company with the mission to improve patient care through innovative echogenic coating solutions for medical devices. Sono-Coat™ is an echogenic coating technology that significantly improves the ultrasound visibility of medical devices in the body leading to better patient outcomes. The unmatched ultrasound visibility of Sono-Coat™ enables doctors carrying out difficult minimally invasive procedures.

open website

Divested in: July 2016

NovioGendix

NovioGendix developed a new biomarker panel for the detection and management of prostate cancer and other cancers. In 2015, MDxHealth acquired NovioGendix. MDxHealth is a multinational healthcare company that provides actionable genomic information to personalize the diagnosis and treatment of cancer.

Divested in: August 2015

Spinnovation

Spinnovation is a contract research organisation specialised in the application of nuclear magnetic resonance (NMR) techniques in the pharmaceutical and biotechnological market. It provides access to a unique combination of applied analytical science expertise, with state-of-the-art technology and innovative approaches.

In 2014, Sinensis Life Sciences acquired Spinnovation. Sinensis Life Sciences is a provider of laboratory testing and manufacturing services to the international life sciences market.

Divested in: September 2014